Skip to main content

Table 3 A comparison of survival outcome data

From: RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial

 

Total

(n = 60)

Saline

(n = 28)

Taurolidine

(n = 32)

p-value

Overall recurrence

6

3

3

1

Recurrence at 2 years

3

2

1

0.389

Mean time to recurrence (months)

 

16.3

28.6

0.4

Median time to recurrence (months)

 

19

38

0.268

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us